Follow
Neil Vasan, MD, PhD
Neil Vasan, MD, PhD
Columbia University Medical Center
Verified email at cumc.columbia.edu - Homepage
Title
Cited by
Cited by
Year
A view on drug resistance in cancer
N Vasan, J Baselga, DM Hyman
Nature 575 (7782), 299-309, 2019
16792019
The genomic landscape of endocrine-resistant advanced breast cancers
P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ...
Cancer cell 34 (3), 427-438. e6, 2018
7822018
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
N Vasan, P Razavi, JL Johnson, H Shao, H Shah, A Antoine, E Ladewig, ...
Science 366 (6466), 714-723, 2019
2112019
Metastasis and immune evasion from extracellular cGAMP hydrolysis
J Li, MA Duran, N Dhanota, WK Chatila, SE Bettigole, J Kwon, RK Sriram, ...
Cancer discovery 11 (5), 1212-1227, 2021
1562021
Dietary fructose improves intestinal cell survival and nutrient absorption
SR Taylor, S Ramsamooj, RJ Liang, A Katti, R Pozovskiy, N Vasan, ...
Nature 597 (7875), 263-267, 2021
1542021
An atlas of substrate specificities for the human serine/threonine kinome
JL Johnson, TM Yaron, EM Huntsman, A Kerelsky, J Song, A Regev, ...
Nature 613 (7945), 759-766, 2023
1492023
Overview of the relevance of PI3K pathway in HR-positive breast cancer
N Vasan, E Toska, M Scaltriti
Annals of oncology 30, x3-x11, 2019
1232019
A RAS renaissance: emerging targeted therapies for KRAS-mutated non–small cell lung cancer
N Vasan, JL Boyer, RS Herbst
Clinical cancer research 20 (15), 3921-3930, 2014
1172014
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
P Razavi, MN Dickler, PD Shah, W Toy, DN Brown, HH Won, BT Li, ...
Nature Cancer 1 (4), 382-393, 2020
1142020
At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy
N Vasan, LC Cantley
Nature Reviews Clinical Oncology 19 (7), 471-485, 2022
642022
A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for …
N Vasan, R Yelensky, K Wang, S Moulder, H Dzimitrowicz, R Avritscher, ...
The oncologist 19 (5), 453-458, 2014
602014
Structure of a C-terminal fragment of its Vps53 subunit suggests similarity of Golgi-associated retrograde protein (GARP) complex to a family of tethering complexes
N Vasan, A Hutagalung, P Novick, KM Reinisch
Proceedings of the National Academy of Sciences 107 (32), 14176-14181, 2010
432010
TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
E Cocco, JE Lee, S Kannan, AM Schram, HH Won, S Shifman, A Kulick, ...
Cancer discovery 11 (1), 126-141, 2021
382021
Phase and context shape the function of composite oncogenic mutations
AN Gorelick, FJ Sánchez-Rivera, Y Cai, CM Bielski, E Biederstedt, ...
Nature 582 (7810), 100-103, 2020
362020
Treating alpelisib-induced hyperglycemia with very low carbohydrate diets and sodium-glucose co-transporter 2 inhibitors: a case series
T Blow, PN Hyde, JN Falcone, A Neinstein, N Vasan, R Chitkara, MA Hurd, ...
Integrative cancer therapies 20, 15347354211032283, 2021
152021
The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity
P Ho, JC Melms, M Rogava, CJ Frangieh, J Poźniak, SB Shah, Z Walsh, ...
Cancer Cell 41 (7), 1207-1221. e12, 2023
132023
A global atlas of substrate specificities for the human serine/threonine kinome
JL Johnson, TM Yaron, EM Huntsman, A Kerelsky, J Song, A Regev, ...
BioRxiv, 2022.05. 22.492882, 2022
102022
Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations
S Sivakumar, DX Jin, R Rathod, J Ross, LC Cantley, M Scaltriti, JW Chen, ...
Clinical Cancer Research 29 (6), 1125-1136, 2023
62023
The CD58: CD2 axis is co-regulated with PD-L1 via CMTM6 and governs anti-tumor immunity
P Ho, JC Melms, M Rogava, CJ Frangieh, SB Shah, Z Walsh, O Kyrysyuk, ...
BioRxiv, 2022.03. 21.485049, 2022
62022
Double PIK3CA mutations in cis enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer
N Vasan, P Razavi, JL Johnson, H Shao, E Reznik, ML Smith, R Sebra, ...
Annals of Oncology 30, iii1, 2019
52019
The system can't perform the operation now. Try again later.
Articles 1–20